ArticleCancer biology & medicine2024
Global, regional, and national burden of early-onset gastric cancer.
Article in Cancer biology & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The incidence of gastric neoplastic lesions in autoimmune gastritis: a systematic review and meta-analysis.Surgical endoscopy · 2026Pooled it
- Molecular features of early- vs. late-onset gastric cancer: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Perioperative outcomes of a novel laparoscopic-like "3-arm + 2-port" model in robot-assisted distal gastrectomy in patients with resectable, non-metastatic gastric cancer: a randomized controlled trial.Journal of robotic surgery · 2026Trial
- Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.International journal of cancer · 2026Trial
- Molecular classification and precision therapy in gastric cancer: Current advances and future perspectives (Review).Oncology reports · 2026Review
- Neutrophil-Macrophage Interactions Shape Inflammatory Macrophage Remodeling in Gastric Cancer During Chemo-Immunotherapy.Cancer science · 2026Article
- Mechanistic Insights into the Action of Histamine-Functionalized PLA Nanoparticles Loaded with 5-Fluorouracil Against Gastric Cancer CellsMolecules (Basel, Switzerland) · 2026Article
- Stage-Dependent Prognostic Impact of Younger Age in Gastric Cancer: A Nationwide Cohort Study.Journal of gastric cancer · 2026Article
- Predictive value of the preoperative systemic immune-inflammation index for primary chemotherapy resistance risk in patients with advanced gastric cancer.Translational cancer research · 2026Article
- A Deep Learning Framework for Gastric Cancer Cell Segmentation with Multi-Scale Attention Mechanisms.Bioengineering (Basel, Switzerland) · 2026Article
- tRF and gastric cancer: molecular mechanism exploration and novel strategies for precision diagnosis and therapy.Journal of translational medicine · 2026Review
- Prognostic Value of the Gustave Roussy Immune Score in Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis.ESMO gastrointestinal oncology · 2026Article
- Global patterns of upper gastrointestinal cancer incidence by subtype and subsite in 2022: a population-based study.Journal of the National Cancer Center · 2026Article
- 1,2,3-Triazole-Linked Chalcones as Privileged Scaffolds in Anticancer Agents.Archiv der Pharmazie · 2026Article
- Development and external validation of a prognostic nomogram for cancer-specific survival in elderly patients with early-stage gastric cancer.Journal of gastrointestinal oncology · 2026Article
- Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review).Oncology letters · 2026Review
- Histopathological subtypes and topographical subsites of gastric cancer in Sub-Saharan Africa: a scoping review.BMC cancer · 2026Article
- Status and trends of early-onset cancers and their risk factors in China: population-based study.Journal of global health · 2026Article
- Advanced breath analysis through hierarchical deep convolutional neural network for multi-cancer screening.NPJ digital medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveThe burden of gastric cancer (GC) across different age groups needs updating. We determined the GC global, regional, and national burden profiles and changes in incidence for 3 sequential 5-year intervals from 2003 to 2017.
methodsThe latest incidence and mortality estimates of GC from 185 countries and regions were extracted from the GLOBOCAN 2022 database. The 5-year interval age-standardised incidence rates (ASIRs) were evaluated using cancer registry data from volumes X-XII of the Cancer Incidence in Five Continents (CI5). Correlation analysis was used to evaluate the relationship between ASIR or the age-standardised mortality rate (ASMR) and the Human Development Index (HDI).
resultsThere was an estimated global 968,000 new GC cases and 660,000 deaths in 2022, with male predominance. GC ASIRs and ASMRs were 9.2 and 6.1 per 100,000 persons, respectively. East Asia had the highest burden, with 53.8% of cases and 48.2% of deaths among all geographic regions. There was a significant correlation between ASIR and HDI. Over three 5-year intervals from 2003 to 2017, the incidence of GC notably decreased in most countries but peaked at 2008-2012 in New Zealand, Turkey, and South Africa. Several countries in Europe, Oceania, and America suggest an increasingly concerning trend among younger individuals, especially females.
conclusionsGC is a significant health issue, especially among males and in geographic regions with an HDI, such as eastern Asia. While the incidence of GC is decreasing in many countries due to prevention efforts and improved treatments, a rising trend persists among younger individuals. Comprehensive prevention strategies tailored to different age patterns are clearly needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.